Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
A study led by the UK's Pirbright Institute has established the first framework for determining the real cost of peste des petits ruminants (PPR) vaccination campaigns.
Zoetis, Merck Animal Health and Biogénesis Bagó have all won Animal Pharm Awards in 2018 – adding to their accolades from previous years.
The Pirbright Institute has revealed new methods for creating a vaccine against Marek's disease and infectious bursal disease (IBD) using CRISPR/CAS9 gene editing.
Merck Animal Health has signed an exclusive global license agreement with US firm Alopexx Vaccine.
Foot-and-mouth disease (FMD) has been rampant in Vietnam and has triggered severe hardship and economic losses for the country's cattle farmers for years. Animal Pharm correspondent Mainbayar Badarch explores how Vietnam has gone about tackling the disease.
Czech Republic-based Bioveta maintained its recent double-digit sales growth into fiscal 2018.
Elanco and Zoetis are among the animal health companies to make recent patent applications in the field of bovine health.
Dutch start-up BunyaVax aims to secure positive study results and series A funding in 2019.
Volker Gerdts has been selected to lead the University of Saskatchewan's Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac).
In 2018, the stand-out M&A deals targeted diagnostics, digital technologies and nutrition. While Zoetis and Merck Animal Health made multi-billion-dollar deals, some of the sector's smaller purchases also hinted towards important trends. Animal Pharm editor Joseph Harvey looks back at where the money was spent.
MSD Animal Health's has purchased Zhejiang ZhengliAntoo Biotech – a privately owned veterinary vaccine specialist based in China – for an undisclosed fee.
German firm AniCon Labor is increasing its sales base for its veterinary diagnostic products and autogenous vaccines outside its domestic market.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.